Advertisement
Mergers and Acquisitions
Subscribe to Mergers and Acquisitions

The Lead

Array BioPharm to Acquire Novartis’ Encorafenib

January 23, 2015 8:23 am | News | Comments

Array BioPharma today announced that it has reached a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development.        

SP Acquires Stability Environments

January 22, 2015 8:38 am | News | Comments

SP Industries, a designer and manufacturer of laboratory equipment, biological drug...

Analyst: Shire Completes ‘Robust’ Deal in $5.2 Billion NPS Pharmaceuticals Acquisition

January 15, 2015 10:55 am | News | Comments

Despite a lofty premium of more than 50% of NPS Pharmaceuticals’ (NPS) unaffected share price,...

Johnson & Johnson Licenses Vedanta's Bowel Disease Drug

January 13, 2015 8:31 am | News | Comments

Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a...

View Sample

FREE Email Newsletter

Tekmira Pharmaceuticals and OnCore Biopharma to Merge

January 12, 2015 11:06 am | News | Comments

Tekmira Pharmaceuticals Corporation and OnCore Biopharma announced today that they have agreed to merge to create a global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.

Capsugel Acquires Monash University’s Proprietary Ionic Liquids Technology

January 12, 2015 9:32 am | News | Comments

This novel technology uses lipid-like counter-ion salts to improve the solubility of drugs in lipid-based liquid, semi-solid and multiparticulate formulations. This technology adds to Capsugel Dosage Form Solutions’ growing suite of bioavailability enhancement technologies and capabilities.

Biogen Idec Acqures Convergence Pharmaceuticals

January 12, 2015 8:32 am | News | Comments

Biogen Idec announced today that it has agreed to acquire U.K.-based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company with a portfolio of ion channel-modulating product candidates for neuropathic pain.     

Advertisement

Shire to Pay $5.2B for NPS Pharma

January 12, 2015 8:28 am | by The Associated Press | News | Comments

The acquisition will expand Shire's portfolio of specialty drugs, medications for niche diseases and conditions that typically command much higher price tags than conventional medications. Shire's best-selling drugs currently include the attention deficit disorder drugs Vyvanse and Adderall XR.

Roche Takes Majority Stake in Foundation Medicine for $1.03B

January 12, 2015 8:23 am | News | Comments

Roche is taking a majority stake in U.S.-based Foundation Medicine in a deal worth $1.03 billion that the Swiss pharmaceutical company says will help it to develop new treatment options for cancer patients.        

AmerisourceBergen to Acquire MWI Veterinary Supply

January 12, 2015 8:10 am | News | Comments

AmerisourceBergen and MWI Veterinary Supply, today announced that they have entered into a definitive merger agreement for AmerisourceBergen to acquire MWI Veterinary Supply (MWI), the leading animal health distribution company in the United States.

Aptuit Sells Two Sites to AMRI

January 9, 2015 8:04 am | News | Comments

Aptuit has divested its aseptic clinical manufacturing site in Glasgow, UK to Albany Molecular Research, Inc., and has entered into a definitive agreement with AMRI to acquire the West Lafayette, Indiana solid-state chemistry business for a total consideration of $60 million.

Hayward Gordon Acquires Sharpe Mixers

January 7, 2015 8:29 am | News | Comments

Based in Seattle, Washington, Sharpe Mixers has served customers for the past 60 years and provides mixing solutions in the chemical, industrial and sanitary markets.  Hayward Gordon intends to make significant investment in plant, equipment and people in Sharpe's Seattle plant to better serve customers in the global market.

Advertisement

Gilead Sciences to Acquire Phenex Pharmaceuticals' Non-Alcoholic Steatohepatitis and Other Liver Diseases Program

January 6, 2015 8:55 am | News | Comments

Gilead Sciences and Phenex Pharmaceuticals AG today announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis.

Pfizer Acquires Redvax GmbH

January 5, 2015 8:05 am | News | Comments

Pfizer has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate.

OncoGenex to Regain Rights to Custirsen from Teva

January 2, 2015 8:56 am | News | Comments

OncoGenex Pharmaceuticals has executed an initial agreement with Teva Pharmaceutical Industries to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.

Lilly Closes Novartis Deal to Create Huge Animal Health Business

January 2, 2015 8:17 am | News | Comments

Just over a week after saying it would sell its heartworm treatment for dogs at the request of federal regulators, Eli Lilly announced that it has completed its $5.4 billion acquisition of the animal health division belonging to Switzerland's Norvartis.

Roivant Acquires SB742457 from GlaxoSmithKline

December 29, 2014 2:42 pm | News | Comments

Roivant Neurosciences has entered into an agreement with GlaxoSmithKline for the acquisition of SB742457, a selective 5-HT6 receptor antagonist with the potential to improve cognition and function in multiple central nervous system disorders.  

Advertisement

Eli Lilly to Sell Heartworm Line for Novartis Deal Approval

December 22, 2014 2:20 pm | News | Comments

The Federal Trade Commission is requiring the sale of Eli Lilly's Sentinel heartworm products because the Novartis deal would reduce competition and lead to higher prices. Eli Lilly will sell Sentinel to French pharmaceutical company Virbac.  

Roche Enters Genomic Informatics Market with Bina Technologies Acquisition

December 22, 2014 9:00 am | News | Comments

Roche has announced the acquisition of Bina Technologies, a privately held company based in Redwood City, California, USA. Bina provides a big data platform for centralized management and processing of next generation sequencing (NGS) data.  

Sartorius Selling Industrial Technologies Division to Minebea Co.

December 22, 2014 8:36 am | News | Comments

Sartorius, an international laboratory and pharmaceutical equipment provider, is selling its Industrial Technologies Division (Intec) to the Japanese Minebea Co., Ltd. (Minebea) and their partner, the Development Bank of Japan Inc.   

Merck Acquires OncoEthix for $110M

December 18, 2014 8:05 am | News | Comments

Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.

PwC: “Perfect Storm” for Corporate Dealmaking Drives M&A Value to Highest Level Since 2007

December 15, 2014 12:10 pm | News | Comments

A wave of corporate mega deal activity drove a significant uptick in M&A value in 2014, according to PwC US. As businesses aim to meet their growth ambitions and increase market share, PwC expects there will be more attractive opportunities for dealmakers to acquire, combine and align with strategic partners in 2015.

Walgreens President and CEO to Retire Following Merger with Alliance Boots

December 10, 2014 4:21 pm | News | Comments

Walgreens announced that Greg Wasson, president and chief executive officer, has informed the company’s board of directors that he will retire shortly after the close of the second step of the Alliance Boots transaction, on which shareholders are scheduled to vote on Dec. 29, 2014.

Cubist Patent Losses Won't Deter Merck

December 9, 2014 10:03 am | by The Associated Press | News | Comments

Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the company's patents protecting its top-selling antibiotic just hours after the deal was announced this week.  

Fitch: Debt-Financed M&A Stressing US Pharma Credit Profiles

December 8, 2014 3:32 pm | News | Comments

The debt-financed acquisition of Cubist Pharmaceuticals by Merck for $9.5 billion is the latest in a string of large, debt-financed acquisitions that are stressing the credit profiles of US healthcare companies, according to Fitch Ratings.  

Natrol Completes Sale to Aurobindo Pharma USA

December 8, 2014 2:00 pm | News | Comments

Natrol has announced the completion of the sale of substantially all of the company’s assets to Aurobindo Pharma USA Inc., a manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, for a purchase price of $132.5M plus assumed liabilities.

Sigma-Aldrich Stockholders Approve Acquisition by Merck KGaA

December 8, 2014 8:50 am | News | Comments

Sigma-Aldrich Corporation stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany at a special meeting of stockholders.       

Merck Buys Cubist Pharmaceuticals for $8.4B

December 8, 2014 7:53 am | News | Comments

Merck is buying Cubist Pharmaceuticals for $8.4 billion, illustrating a new emphasis on combating so-called "superbugs" that are drawing dire warnings from global health organizations.           

Noble Life Sciences Acquires Spring Valley Laboratories

December 3, 2014 10:38 am | News | Comments

Noble Life Sciences, a provider of preclinical drug development services, has announced the acquisition of Spring Valley Laboratories, a full service, GLP-compliant, preclinical contract research organization for the development of drugs, vaccines, and medical devices.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading